ERO1A与恶性肿瘤相关性的研究进展

耿文倩 ,  李欣岩 ,  蒋彬 ,  孙志英 ,  李婉明

中国医科大学学报 ›› 2026, Vol. 55 ›› Issue (8) : 760 -765.

PDF (389KB)
中国医科大学学报 ›› 2026, Vol. 55 ›› Issue (8) : 760 -765. DOI: 10.12007/j.issn.0258‐4646.2026.08.014
综述

ERO1A与恶性肿瘤相关性的研究进展

作者信息 +

Advances in research on the relationship between ERO1A and malignant tumors

Author information +
文章历史 +
PDF (397K)

摘要

内质网氧化还原酶1A (ERO1A) 是一种含有黄素腺苷二核苷酸的内质网驻留硫醇氧化还原酶,属于内质网氧化还原酶家族。ERO1A参与细胞内多种活动的调节,如新生肽二硫键的形成、内质网氧化环境的维持和内质网应激的调控等。ERO1A与多种肿瘤的发生和发展密切相关,在结直肠癌、胰腺癌、肝癌、乳腺癌、肺癌等恶性肿瘤中异常表达,可通过调控内质网应激、肿瘤糖酵解代谢、血管生成和细胞凋亡等过程,促进肿瘤增殖、侵袭和转移。本文总结了ERO1A的分子结构和功能及其近年来在多种恶性肿瘤中的相关研究,为恶性肿瘤的诊断和治疗提供参考。

Abstract

Endoplasmic reticulum oxidoreductin 1A (ERO1A) is an endoplasmic reticulum-resident thiol oxidoreductase that contains a flavin adenine dinucleotide and belongs to the endoplasmic reticulum oxidoreductase family. ERO1A modulates diverse intracellular biological processes,including de novo disulfide bond formation in nascent polypeptides,maintenance of endoplasmic reticulum oxidative homeostasis,and regulation of endoplasmic reticulum stress. Closely implicated in the initiation and progression of multiple malignant tumors,ERO1A is aberrantly expressed in colorectal cancer,pancreatic cancer,hepatocellular carcinoma,breast cancer,lung adenocarcinoma,and other neoplasms. By governing endoplasmic reticulum stress,tumor glycolytic metabolism,angiogenesis,and cellular apoptosis,ERO1A facilitates tumor proliferation,invasion,and metastasis. This review addresses the molecular structure and biological functions of ERO1A as well as recent research advances regarding its roles in various malignant tumors,thereby providing evidence-based references for the diagnosis of malignant tumors and advanced therapeutic development.

关键词

内质网氧化还原酶1A / 恶性肿瘤 / 转移 / 血管生成

Key words

endoplasmic reticulum oxidoreductin 1A / malignant tumor / metastasis / angiogenesis

引用本文

引用格式 ▾
耿文倩,李欣岩,蒋彬,孙志英,李婉明. ERO1A与恶性肿瘤相关性的研究进展[J]. 中国医科大学学报, 2026, 55(8): 760-765 DOI:10.12007/j.issn.0258‐4646.2026.08.014

登录浏览全文

4963

注册一个新账户 忘记密码

参考文献

[1]

MAY D,ITIN A,GAL O,et al. Ero1-Lα plays a key role in a HIF-1-mediated pathway to improve disulfide bond formation and VEGF secretion under hypoxia:implication for cancer [J]. Oncogene,2005,24 (6):1011-1020. DOI:10.1038/sj.onc.1208325.

[2]

VEMBAR SS,BRODSKY JL. One step at a time:endoplasmic reticulum-associated degradation [J]. Nat Rev Mol Cell Biol,2008,9 (12):944-957. DOI:10.1038/nrm2546.

[3]

SCHWARZ DS,BLOWER MD. The endoplasmic reticulum:structure,function and response to cellular signaling [J]. Cell Mol Life Sci, 2016,73 (1):79-94. DOI:10.1007/s00018-015-2052-6.

[4]

LEE S,LEE E,KO E,et al. Tumor-associated macrophages secrete CCL2 and induce the invasive phenotype of human breast epithelial cells through upregulation of ERO1-α and MMP-9 [J]. Cancer Lett, 2018,437:25-34. DOI:10.1016/j.canlet.2018.08.025.

[5]

TANAKA T,KUTOMI G,KAJIWARA T,et al. Cancer-associated oxidoreductase ERO1-α promotes immune escape through up-regulation of PD-L1 in human breast cancer [J]. Oncotarget,2017,8 (15):24706-24718. DOI:10.18632/oncotarget.14960.

[6]

INABA K,MASUI S,IIDA H,et al. Crystal structures of human Ero1α reveal the mechanisms of regulated and targeted oxidation of PDI [J]. EMBO J,2010,29 (19):3330-3343. DOI:10.1038/emboj.2010.222.

[7]

WAYPA GB,MARKS JD,GUZY R,et al. Hypoxia triggers subcellular compartmental redox signaling in vascular smooth muscle cells [J]. Circ Res,2010,106 (3):526-535. DOI:10.1161/CIRCRESAHA.109.206334.

[8]

VARONE E,CHERNORUDSKIY A,CHERUBINI A,et al. ERO1 alpha deficiency impairs angiogenesis by increasing N-glycosylation of a proangiogenic VEGFA [J]. Redox Biol,2022,56:102455. DOI:10.1016/j.redox.2022.102455.

[9]

ZHOU B,WANG G,GAO S,et al. Expression of ERO1L in gastric cancer and its association with patient prognosis [J]. Exp Ther Med, 2017,14 (3):2298-2302. DOI:10.3892/etm.2017.4782.

[10]

LIU L,WANG C,LI S,et al. ERO1L is a novel and potential biomarker in lung adenocarcinoma and shapes the immune-suppressive tumor microenvironment [J]. Front Immunol,2021,12:677169. DOI:10.3389/fimmu.2021.677169.

[11]

GUPTA N,PARK JE,TSE W,et al. ERO1α promotes hypoxic tumor progression and is associated with poor prognosis in pancreatic cancer [J]. Oncotarget,2019,10 (57):5970-5982. DOI:10.18632/oncotarget.27235.

[12]

YANG S,YANG C,YU F,et al. Endoplasmic reticulum resident oxidase ERO1-Lalpha promotes hepatocellular carcinoma metastasis and angiogenesis through the S1PR1/STAT3/VEGF-A pathway [J]. Cell Death Dis,2018,9:1105. DOI:10.1038/s41419-018-1134-4.

[13]

VARONE E,DECIO A,CHERNORUDSKIY A,et al. The ER stress response mediator ERO1 triggers cancer metastasis by favoring the angiogenic switch in hypoxic conditions [J]. Oncogene,2021,40 (9):1721-1736. DOI:10.1038/s41388-021-01659-y.

[14]

VORONKOVA MA,JOHNSON B,GANDHI N,et al. ERO1A levels are a prognostic indicator in EGFR mutated non small cell lung cancer [J]. NPJ Precis Oncol,2024,8:250. DOI:10.1038/s41698-024-00736-1.

[15]

JOHNSON BD,GELDENHUYS WJ,HAZLEHURST LA. The role of ERO1α in modulating cancer progression and immune escape [J]. J Cancer Immunol,2020,2:103-115. DOI:10.33696/cancerimmunol.2.023.

[16]

LI C,LEI S,DING L,et al. Global burden and trends of lung cancer incidence and mortality [J]. Chin Med J (Engl),2023,136 (13):1583-1590. DOI:10.1097/CM9.0000000000002529.

[17]

ZHU J,WANG M,HU D. Development of an autophagy-related gene prognostic signature in lung adenocarcinoma and lung squamous cell carcinoma [J]. PeerJ,2020,8:e8288. DOI:10.7717/peerj.8288.

[18]

ZHOU J,LIU B,LI Z,et al. Proteomic analyses identify differentially expressed proteins and pathways between low-risk and high-risk subtypes of early-stage lung adenocarcinoma and their prognostic impacts [J]. Mol Cell Proteom,2021,20:100015. DOI:10.1074/mcp.RA120.002384.

[19]

CHEN G,WANG Q,WANG K. MicroRNA-218-5p affects lung adenocarcinoma progression through targeting endoplasmic reticulum oxidoreductase 1 alpha [J]. Bioengineered,2022,13 (4):10061-10070. DOI:10.1080/21655979.2022.2063537.

[20]

XIE J,LIAO G,FENG Z,et al. ERO1L promotes the proliferation and metastasis of lung adenocarcinoma via the Wnt2/β-catenin signaling pathway [J]. Mol Carcinog,2022,61 (10):897-909. DOI:10.1002/mc.23441.

[21]

LEI Y,ZANG R,LU Z,et al. ERO1L promotes IL6/sIL6R signaling and regulates MUC16 expression to promote CA125 secretion and the metastasis of lung cancer cells [J]. Cell Death Dis,2020,11:853. DOI:10.1038/s41419-020-03067-8.

[22]

LIU L,LI S,QU Y,et al. Ablation of ERO1A induces lethal endoplasmic reticulum stress responses and immunogenic cell death to activate anti-tumor immunity [J]. Cell Rep Med,2023,4 (10):101206. DOI:10.1016/j.xcrm.2023.101206.

[23]

BERTUCCI F,NG CKY,PATSOURIS A,et al. Genomic characterization of metastatic breast cancers [J]. Nature,2019,569 (7757):560-564. DOI:10.1038/s41586-019-1056-z.

[24]

TANAKA T,KAJIWARA T,et al. Cancer-associated oxidoreductase ERO1-α drives the production of tumor-promoting myeloid-derived suppressor cells via oxidative protein folding [J]. J Immunol,2015, 194 (4):2004-2010. DOI:10.4049/jimmunol.1402538.

[25]

KUTOMI G,TAMURA Y,TANAKA T,et al. Human endoplasmic reticulum oxidoreductin 1-α is a novel predictor for poor prognosis of breast cancer [J]. Cancer Sci,2013,104 (8):1091-1096. DOI:10.1111/cas.12177.

[26]

ZILLI F,MARQUES RAMOS P,AUF DER MAUR P,et al. The NFIB‐ERO1A axis promotes breast cancer metastatic colonization of disseminated tumour cells [J]. EMBO Mol Med,2021,13 (4):e13162. DOI:10.15252/emmm.202013162.

[27]

TANAKA T,KUTOMI G,KAJIWARA T,et al. Cancer-associated oxidoreductase ERO1-α drives the production of VEGF via oxidative protein folding and regulating the mRNA level [J]. Br J Cancer, 2016,114 (11):1227-1234. DOI:10.1038/bjc.2016.105.

[28]

VARONE E,RETINI M,CHERUBINI A,et al. Small molecule-mediated inhibition of the oxidoreductase ERO1A restrains aggressive breast cancer by impairing VEGF and PD-L1 in the tumor microenvironment [J]. Cell Death Dis,2025,16 (1):105. DOI:10.1038/s41419-025-07426-1.

[29]

WANG Z,ZONG H,LIU W,et al. Augmented ERO1α upon mTORC1 activation induces ferroptosis resistance and tumor progression via upregulation of SLC7A11 [J]. J Exp Clin Cancer Res, 2024,43 (1):112. DOI:10.1186/s13046-024-03039-2.

[30]

VARONE E,DECIO A,BARBERA MC,et al. Endoplasmic reticulum oxidoreductin 1-alpha deficiency and activation of protein translation synergistically impair breast tumour resilience [J]. Br J Pharmacol,2022,179 (23):5180-5195. DOI:10.1111/bph.15927.

[31]

BRAY F,LAVERSANNE M,SUNG H,et al. Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin,2024,74 (3):229-263. DOI:10.3322/caac.21834.

[32]

CHEN P,CHEN Y,SHARMA A,et al. Inhibition of ERO1L induces autophagy and apoptosis via endoplasmic reticulum stress in colorectal cancer [J]. Cell Signal,2025,127:111560. DOI:10.1016/j.cellsig.2024.111560.

[33]

WALTER P,RON D. The unfolded protein response:from stress pathway to homeostatic regulation [J]. Science,2011,334 (6059):1081-1086. DOI:10.1126/science.1209038.

[34]

WANG G,HAN J,WANG G,et al. ERO1α mediates endoplasmic reticulum stress-induced apoptosis via microRNA-101/EZH2 axis in colon cancer RKO and HT-29 cells [J]. Hum Cell,2021,34 (3):932-944. DOI:10.1007/s13577-021-00494-3.

[35]

LUO W,HE D,ZHANG J,et al. Knockdown of PPARδ induces VEGFA-mediated angiogenesis via interaction with ERO1A in human colorectal cancer [J]. Front Oncol,2021,11:713892. DOI:10.3389/fonc.2021.713892.

[36]

SHIBUYA KC,GOEL VK,XIONG W,et al. Pancreatic ductal adenocarcinoma contains an effector and regulatory immune cell infiltrate that is altered by multimodal neoadjuvant treatment [J]. PLoS One,2014,9 (5):e96565. DOI:10.1371/journal.pone.0096565.

[37]

ZHANG J,YANG J,LIN C,et al. Endoplasmic reticulum stress-dependent expression of ERO1L promotes aerobic glycolysis in pancreatic cancer [J]. Theranostics,2020,10 (18):8400-8414. DOI:10.7150/thno.45124.

[38]

TAY AHM,CINOTTI R,SZE NSK,et al. Inhibition of ERO1a and IDO1 improves dendritic cell infiltration into pancreatic ductal adenocarcinoma [J]. Front Immunol,2023,14:1264012. DOI:10.3389/fimmu.2023.1264012.

[39]

CHIDAMBARANATHAN-REGHUPATY S,FISHER PB,SARKAR D. Hepatocellular carcinoma (HCC):epidemiology,etiology and molecular classification [J]. Adv Cancer Res,2021,149:1-61. DOI:10.1016/bs.acr.2020.10.001.

[40]

SHEN J,JIAO Y,DING N,et al. Homocysteine facilitates endoplasmic reticulum stress and apoptosis of hepatocytes by suppressing ERO1α expression via cooperation between DNMT1 and G9a [J]. Cell Biol Int,2022,46 (8):1236-1248. DOI:10.1002/cbin.11805.

[41]

PITT JM,MARABELLE A,EGGERMONT A,et al. Targeting the tumor microenvironment:removing obstruction to anticancer immune responses and immunotherapy [J]. Ann Oncol,2016,27 (8):1482-1492. DOI:10.1093/annonc/mdw168.

[42]

LU C,LIU Y,ALI NM,et al. The role of innate immune cells in the tumor microenvironment and research progress in anti-tumor therapy [J]. Front Immunol,2023,13:1039260. DOI:10.3389/fimmu.2022.1039260.

[43]

BELGIOVINE C,D’INCALCI M,ALLAVENA P,et al. Tumor-associated macrophages and anti-tumor therapies:complex links [J]. Cell Mol Life Sci,2016,73 (13):2411-2424. DOI:10.1007/s00018-016-2166-5.

[44]

BISWAS SK,MANTOVANI A. Macrophage plasticity and interaction with lymphocyte subsets:cancer as a paradigm [J]. Nat Immunol,2010,11 (10):889-896. DOI:10.1038/ni.1937.

基金资助

国家自然科学基金(82373445)

AI Summary AI Mindmap
PDF (389KB)

0

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉